NOW RECRUITING: Patients with Pulmonary Arterial Hypertension (PAH) for IMPAHCT,
a Phase 2b/3 study evaluating AV-101. Learn more about the study.

Tim Pigot

Tim has over 25 years of industry experience in launching and commercializing a range of products over multiple therapeutic areas. These include leading the launches of multiple products in rare cardiopulmonary diseases such as Revatio and Letairis in pulmonary arterial hypertension, Cayston in cystic fibrosis, and preparing for the launch of mavacamten in obstructive hypertrophic cardio-myopathy.